- Co-Diagnostics is well positioned to benefit from incremental fundamental momentum seen at the back end of 2020.
- The company's Covid-19 tests are differentiated by distinguishing between common cold and SARS-CoV-2 with an easy to use platform.
- Given the epidemiology of the common cold and influenza A+B, testing volumes will likely remain high as an exclusion barrier to Covid-19 spread.
- We feel the market is unfairly discounting shares and believe shares are worth ~13-$20 in the base and upside case.
- Here, we provide investors with additional factors for consideration in the investment debate.
For further details see:
Co-Diagnostics: Additional Factors For Consideration In The Investment Debate